Gene Solutions, a prominent player in mitochondrial dysfunction genomics, has reinforced its research and development (R&D) dominance in Advanced Neurotherapeutics for Alzheimer's, Parkinson's, and Related Disorders with the recent Patent Publication (WO 2025 168944 A1) and subsequent PCT filing. The company, based in Charlottesville, Virginia, unveiled this significant development on September 11, 2025. This move underscores their commitment to tackling neurological conditions, with a focus on these debilitating diseases.